IRWD — Ironwood Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $498.96m
- $868.18m
- $296.15m
Annual cashflow statement for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 528 | 175 | -1,032 | 0.88 | 24 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 48.7 | 30 | 1,131 | 33.4 | 20.7 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 16.5 | 1.49 | 9.84 | -0.819 | 39.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 262 | 274 | 183 | 104 | 127 |
| Capital Expenditures | -0.265 | -0.136 | -1,026 | -0.142 | -0.034 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.265 | -0.136 | -1,026 | -0.142 | -0.034 |
| Financing Cash Flow Items | 0 | — | -29.2 | -2.98 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4.55 | -238 | 277 | -107 | 0.216 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 257 | 36.1 | -566 | -3.6 | 127 |